Skip to content

Survey of Patient Engagement and Attitudes towards Key research priorities in Lung cancer - korero tahi

Survey of Patient Engagement and Attitudes towards Key research priorities in Lung cancer - korero tahi

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12624001275550
Acronym
SPEAK - Lung
Enrollment
500
Registered
2024-10-18
Start date
2024-10-21
Completion date
2025-01-31
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Lung Cancer is the leading cause of cancer-related death in Aotearoa New Zealand. This disproportionately affects Maori who have higher incidence of lung cancer and higher rates of mortality due to lung cancer. In recent years the treatment of advanced lung cancer has been transformed by the advent of Immune Checkpoint Inhibitors (immunotherapy), which has led to significant improvements in survival. Immunotherapy for advanced lung cancer in New Zealand has been funded by Pharmac since April 2023. We are still learning how to maximise the benefits of this therapy in a New Zealand ontext. In the Auckland region, medical oncology services are provided by Te Puriri o Te Ora and immunotherapy can currently only be delivered from a single location in Auckland City Hospital, central Auckland. This may represent a barrier to treatment from some patients and presents an equity problem for the portion of the patient population who need to travel to receive treatment. The direction of modelling for the northern region cancer service is moving towards care closer to home and with it a new type of workforce. This study plans to survey all patients attending in-person medical oncology thoracic cancer clinic appointments at Auckland Hospital in a 3 month period. We would like to accurately assess selfidentified ethnicity in our patient group, to determine if current hospital records accurately represent this. The survey will ask about patients preference of setting and location to receive immunotherapy. The results will help to inform the planned pilot of delivering community- based immunotherapy with Maori Primary Care Providers. Ongoing clinical and scientific research is required to continue to improve the equitable access to effective lung cancer treatments such as immunotherapy in New Zealand and infrastructure such as governed biobanking and reliable clinical data are needed for future improvements including discovery of biomarkers for treatment response.

Interventions

Patient Questionnaire This is a single arm observational study. Participants attending an in-person medical assessment will be provided a Patient Information Sheet (PIS) when the check in with the receptionist. The PIS will be provided in the format of a printed leaflet which with information about participation in the study and a range of contact details to reach study investigators with questions and to access cultural support if required. The patient will retain the PIS for their own records

Patient Questionnaire This is a single arm observational study. Participants attending an in-person medical assessment will be provided a Patient Information Sheet (PIS) when the check in with the receptionist. The PIS will be provided in the format of a printed leaflet which with information about participation in the study and a range of contact details to reach study investigators with questions and to access cultural support if required. The patient will retain the PIS for their own records. An investigator will be in attendance at all clinics to provide assistance to participants and answer questions. Patients who indicate they wish to participate will be offered the survey in an electronic format on tablet computer. Where the survey is completed electronically, the consent form will also be completed electronically on the same device. Electronic consent will be stored securely as a .pdf document which will be archived and stored securely, separate to the results of the survey, in accordance with the data management plan. A paper consent form and survey, with identical text and content, will also be available and can be offered to any patients who are not able to complete the electronic version. Investigators will preferentially offer the electronic edition whenever possible in order to increase the efficiency and accuracy of data collection. In this survey, the PIS will be provided separately from the consent form, in order that the patient can retain patient information and contact details, whilst allowing for consent to be incorporated into the electronic survey. The questionnaire contains a total of 8 questions, covering four topics. We anticipate the survey can be completed in 5-10minutes. It is designed to be completed by the participant themselves, or with assistance from whanau (family). We anticipate the PIC and questionnaire can be completed whilst in the clinic waiting room, without any impact on standard clinical care. Questions include responses recorded on a Likert scale. Questions which include the option for free text answers will be reviewed by the investigators in order to inform the content and design of future studies but will not be formally assessed with qualitative analysis. The title of the study utilises the Te Reo Maori words 'korero tahi', which can be translated as 'taking together'. Te Reo Maori is an official language of Aotearoa/New Zealand, the jurisdiction in which the study will take place. Inclusion of the maori population is a priority for the investigators of this study. We have intentionally utilised Maori language in title of this study to forward the goal of inclusion and participation.

Sponsors

University of Auckland
Lead SponsorUniversity

Eligibility

Sex/Gender
All
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients attending an in-person Medical Oncology outpatient appointment in thoracic tumour stream clinic with a diagnosis of Lung Cancer in the Auckland region of New Zealand

Exclusion criteria

1. Clinic attendee with Non-lung cancer diagnosis (eg. Mesothelioma and Thymoma) 2. Patients not attending clinic in-person, eg telephone or videoconference appointments 3. Unable to provide informed consent 4. Unable to participate due to poor performance status or medical instability 5. Children aged under 16 are not within the scope of this survey

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026